Shalabi Manar G, Abbas Anass M, Mills Jeremy, Kheirelseid Mohamed A, Elderdery Abozer Y
Clinical Laboratory Sciences Department, College of Applied Medical Sciences, Jouf University, Sakakah, Saudi Arabia.
Medical Laboratory Sciences Department, Nahda College, Khartoum, Sudan.
Breast Cancer (Auckl). 2021 Feb 25;15:1178223421998354. doi: 10.1177/1178223421998354. eCollection 2021.
Two estrogen receptor isoforms (ERα and ERβ) have been characterized with variable and sometimes contrasting responses to estrogens, partially explained by different receptor signaling pathways in estrogen-sensitive tissues. This is a retrospective, descriptive, cross-sectional study, aiming to evaluate the expression pattern of ERβ, employing immunohistochemical techniques using specific monoclonal antibody for ERβ, to correlate its expression with that of ERα in a Sudanese population. Two-hundred and fifty formalin-fixed paraffin-wax-embedded breast tissue blocks were used in this study. Of these, 200 were taken from breast cancer patients ascertained as study cases, and the remaining 50 were noninvolved surgical margin considered as normal breast tissue. Receptor expression was demonstrated using immunohistochemical techniques. The immune expression of ERβ was detected in 57.5% of breast cancers. It was differentially expressed in breast tissues encompassing normal, noninvasive, as well as invasive carcinoma ( = .02). There was no evidence of a significant relationship between ERβ and ERα expression. Among the ERα-negative tumor, 60.4% expressed ERβ. The expression of ERβ among this subgroup was significantly associated with good clinicopathological parameters such as negative Her2/neu, lower grade, and negative lymph node metastasis ( = .002). This study concludes that ERβ was commonly expressed among Sudanese patients with breast cancer, either co-expressed with ERα or expressed alone. In the ERα-negative subgroup, it was associated with better tumor outcomes suggesting ERβ should be included in the diagnostic protocol as an independent marker for favorable prognosis.
已鉴定出两种雌激素受体亚型（ERα和ERβ），它们对雌激素有不同的反应，有时甚至相互矛盾，这在一定程度上可由雌激素敏感组织中不同的受体信号通路来解释。这是一项回顾性、描述性横断面研究，旨在评估ERβ的表达模式，采用针对ERβ的特异性单克隆抗体的免疫组织化学技术，以关联其在苏丹人群中的表达与ERα的表达。本研究使用了250个福尔马林固定石蜡包埋的乳腺组织块。其中，200个取自确诊为研究病例的乳腺癌患者，其余50个为未受累手术切缘，被视为正常乳腺组织。使用免疫组织化学技术显示受体表达。在57.5%的乳腺癌中检测到ERβ的免疫表达。它在包括正常、非侵袭性以及侵袭性癌的乳腺组织中差异表达（P = 0.02）。没有证据表明ERβ和ERα表达之间存在显著关系。在ERα阴性肿瘤中，60.4%表达ERβ。该亚组中ERβ的表达与良好的临床病理参数显著相关，如Her2/neu阴性、低级别和阴性淋巴结转移（P = 0.002）。本研究得出结论，ERβ在苏丹乳腺癌患者中普遍表达，要么与ERα共表达，要么单独表达。在ERα阴性亚组中，它与更好的肿瘤预后相关，表明ERβ应作为有利预后的独立标志物纳入诊断方案。
